CLINUVEL PHARMACEUTICALS

We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.

CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In December 2014 the European Commission granted SCENESSE® marketing authorisation under exceptional circumstances for the prevention of phototoxicity in adult patients with EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

Latest Company Announcements

23 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More
20 December 2016

CLINUVEL Newsletter - December 2016

At the end of a calendar year we look back on plenty of activities and a solid financial performance by the CLINUVEL Group.

Read More
12 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More
28 November 2016

Results of Meeting

AGM results

Read More
27 November 2016

Chair's Address to the Annual General Meeting

I would like to commence my address by saying it is always a pleasure to welcome familiar and a few new faces to the CLINUVEL Annual General meeting.

Read More

Quick Links